Researchers have developed an inexpensive blood test they say can predict a pregnant women’s due date and potentially identify women at risk for of preterm birth; Virginia's governor has expanded Medicaid in the state; and the American Medical Association is expected to take a stance on over-the-counter birth control this weekend.
Scientists have developed a blood test they say can be used to predict a pregnant woman’s due date and potentially identify women at risk for giving birth prematurely. The New York Times reported that the research, which is still in preliminary stages, detects changes in RNA in a pregnant woman’s blood and can estimate due dates within 2 weeks in nearly half the cases. According to researchers, the inexpensive test is as accurate as ultrasound, the current and more expensive method.
Virginia Governor Ralph Northam has signed off on a budget that includes Medicaid expansion for the state. According to The Hill, the expansion is estimated to provide health insurance to up to 400,000 people. The expansion includes work requirements for Medicaid recipients and marks the 33rd state to expand Medicaid.
As pressure mounts for drug makers to sell birth control over the counter, the American Medical Association (AMA) is expected to take a stance on the issue during its annual meeting in Chicago this weekend, reported STAT News. According to the news outlet, delegates from nation’s largest physicians group are expected to vote on a resolution to encourage birth control manufacturers to submit applications to the FDA to switch the status of their pills from prescription to over the counter.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More